ANTIPLATELET THERAPY IN HIGH-RISK STROKE PATIENTS: REAL-WORLD EVIDENCE
Main Article Content
Keywords
.
Abstract
Stroke is a major global health burden and one of the leading causes of disability and mortality worldwide. According to the World Health Organization (WHO), stroke accounts for approximately 5.5 million deaths annually, with a significant proportion of survivors experiencing long-term disability. In India, stroke incidence has been rising due to aging populations, increased prevalence of hypertension and diabetes, and lifestyle changes. Among the different types of strokes, ischemic stroke is the most common, constituting about 75% of all stroke cases, followed by hemorrhagic stroke and transient ischemic attack (TIA).
Antiplatelet therapy is a cornerstone of secondary prevention of ischemic stroke. Patients with a history of stroke or TIA have a high risk of recurrent events, which can be debilitating or fatal. Antiplatelet drugs such as aspirin, clopidogrel, and ticagrelor reduce platelet aggregation, thereby preventing clot formation in the arteries supplying blood to the brain. Dual antiplatelet therapy (DAPT)—a combination of two antiplatelet agents—is sometimes prescribed for high-risk patients to provide greater protection against recurrent strokes. However, balancing the benefits of stroke prevention with the risk of bleeding complications remains a clinical challenge.
References
2. Wang, Y., Wang, Y., Zhao, X., Liu, L., Wang, D., Wang, C., et al. (2013). Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New England Journal of Medicine, 369(1), 11-19. https://doi.org/10.1056/NEJMoa1215340
3. Diener, H. C., & Hankey, G. J. (2020). Primary and secondary prevention of ischemic stroke and cerebral ischemia. Journal of the American College of Cardiology, 75(15), 1804-1818. https://doi.org/10.1016/j.jacc.2020.01.049
4. Hackam, D. G., & Spence, J. D. (2019). Antiplatelet therapy in ischemic stroke and transient ischemic attack. Stroke, 50(3), 773-778. https://doi.org/10.1161/STROKEAHA.118.023769
5. Sacco, R. L., Kasner, S. E., Broderick, J. P., Caplan, L. R., Connors, J. J., Culebras, A., et al. (2013). An updated definition of stroke for the 21st century. Stroke, 44(7), 2064-2089. https://doi.org/10.1161/STR.0b013e318296aeca
6. Albers, G. W., Marks, M. P., Kemp, S., Christensen, S., Tsai, J. P., Ortega-Gutierrez, S., et al. (2018). Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. New England Journal of Medicine, 378(8), 708-718. https://doi.org/10.1056/NEJMoa1713973
7. Amarenco, P., Lavallée, P. C., Labreuche, J., Albers, G. W., Bornstein, N. M., Canhão, P., et al. (2016). One-year risk of stroke after transient ischemic attack or minor stroke. New England Journal of Medicine, 374(16), 1533-1542. https://doi.org/10.1056/NEJMoa1412981
8. Bath, P. M., & Lees, K. R. (2000). ABCD2 score: Improving stroke risk prediction in TIA patients. Lancet Neurology, 9(10), 947-956. https://doi.org/10.1016/S1474-4422(10)70170-5
9. Rothwell, P. M., Algra, A., & Amarenco, P. (2011). Medical treatment in acute and long-term secondary prevention after transient ischemic attack and ischemic stroke. Lancet, 377(9778), 1681-1692. https://doi.org/10.1016/S0140-6736(11)60550-4
10. Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., et al. (2014). Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke, 45(7), 2160-2236. https://doi.org/10.1161/STR.0000000000000024
11. Ntaios, G., Michel, P., Georgiopoulos, G., Guo, Y., Li, W., Xiong, J., et al. (2020). Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke. Stroke, 51(9), e254-e258. https://doi.org/10.1161/STROKEAHA.120.031208
12. Amarenco, P., Kim, J. S., Labreuche, J., Charles, H., Abtan, J., Béjot, Y., et al. (2018). A comparison of two LDL cholesterol targets after ischemic stroke. New England Journal of Medicine, 379(10), 920-931. https://doi.org/10.1056/NEJMoa1800757
13. Hankey, G. J. (2017). Secondary stroke prevention. Lancet Neurology, 16(11), 984-995. https://doi.org/10.1016/S1474-4422(17)30261-6
14. Greving, J. P., Schrag, M., & Rothwell, P. M. (2013). Risk prediction scores for recurrent vascular events after TIA or stroke. Lancet, 382(9890), 195-204. https://doi.org/10.1016/S01406736(13)60842-5
15. Shah, R., Wilkins, E., Nichols, M., Kelly, P., El-Sayed, H., Timmis, A., et al. (2019). Epidemiology of stroke in Europe. European Heart Journal, 40(14), 1246-1256. https://doi.org/10.1093/eurheartj/ehz215
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Deepak Kumar Punna
KVK College of Pharmacy, Surrmaiguda, Abullapuramet, RR Dist.
Sumana Chatla
KVK College of Pharmacy, Surrmaiguda, Abullapuramet, RR Dist.
Ameesha Kumari Sharma
KVK College of Pharmacy, Surrmaiguda, Abullapuramet, RR Dist.
Dr. Chirapu Sainadh Reddy
Vaagdevi Institute of Pharmaceutical Sciences, Bollikunta, Warangal- 506 005